Psoriasis classification: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
m (Bot: Removing from Primary care)
 
(19 intermediate revisions by 5 users not shown)
Line 4: Line 4:


==Overview==
==Overview==
Psoriasis can be classified according to clinical appearance, [[Morphology (biology)|morphology]], and localization. According to the International Psoriasis Council, psoriasis may be classified into four subtypes: plaque-type psoriasis, guttate psoriasis, generalized pustular psoriasis (GPP), and [[erythroderma]]. Several further subphenotypes have been named according to distribution (localized vs. widespread), [[anatomical]] localization (flexural - also called inverse, [[scalp]], [[Palms of the hands|palms]]/[[soles]]/nail), size (large vs. small) and thickness (thick vs. thin) of [[Plaque|plaques]], onset (early vs. late), and disease activity (active vs. stable).
Psoriasis can be classified according to clinical appearance, [[Morphology (biology)|morphology]], and localization. According to the International Psoriasis Council, psoriasis may be classified into four subtypes: plaque-type psoriasis, guttate psoriasis, generalized pustular psoriasis (GPP), and [[erythroderma]]. Several further subphenotypes have been named according to distribution (localized vs. widespread), [[anatomical]] localization (flexural or inverse, [[scalp]], [[Palms of the hands|palms]]/[[soles]]/nail), size (large vs. small) and thickness (thick vs. thin) of [[Plaque|plaques]], onset (early vs. late), and disease activity (active vs. stable).


==Classification==
==Classification==


=== Classification based on clinical appearance, morphology, and localization ===
=== Classification based on clinical appearance, morphology, and localization ===
*The International Psoriasis Council classifies psoriasis into four main forms, according to clinical appearance, [[Morphology (biology)|morphology]] and localization:   
*The International Psoriasis Council classifies psoriasis into four main forms, according to clinical appearance, [[Morphology (biology)|morphology]] and localization:<ref name="pmid2530253">{{cite journal |vauthors=Boyd AS, Menter A |title=Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients |journal=J. Am. Acad. Dermatol. |volume=21 |issue=5 Pt 1 |pages=985–91 |year=1989 |pmid=2530253 |doi= |url=}}</ref><ref name="pmid12362257">{{cite journal |vauthors=Tauscher AE, Fleischer AB, Phelps KC, Feldman SR |title=Psoriasis and pregnancy |journal=J Cutan Med Surg |volume=6 |issue=6 |pages=561–70 |year=2002 |pmid=12362257 |doi=10.1177/120347540200600608 |url=}}</ref><ref name="pmid2878015">{{cite journal |vauthors=Abel EA, DiCicco LM, Orenberg EK, Fraki JE, Farber EM |title=Drugs in exacerbation of psoriasis |journal=J. Am. Acad. Dermatol. |volume=15 |issue=5 Pt 1 |pages=1007–22 |year=1986 |pmid=2878015 |doi= |url=}}</ref><ref name="pmid23971052">{{cite journal |vauthors=Skroza N, Proietti I, Pampena R, La Viola G, Bernardini N, Nicolucci F, Tolino E, Zuber S, Soccodato V, Potenza C |title=Correlations between psoriasis and inflammatory bowel diseases |journal=Biomed Res Int |volume=2013 |issue= |pages=983902 |year=2013 |pmid=23971052 |pmc=3736484 |doi=10.1155/2013/983902 |url=}}</ref><ref name="pmid22751586">{{cite journal |vauthors=Gelfand JM, Yeung H |title=Metabolic syndrome in patients with psoriatic disease |journal=J Rheumatol Suppl |volume=89 |issue= |pages=24–8 |year=2012 |pmid=22751586 |pmc=3670770 |doi=10.3899/jrheum.120237 |url=}}</ref><ref name="pmid23845151">{{cite journal |vauthors=Pouplard C, Brenaut E, Horreau C, Barnetche T, Misery L, Richard MA, Aractingi S, Aubin F, Cribier B, Joly P, Jullien D, Le Maître M, Ortonne JP, Paul C |title=Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies |journal=J Eur Acad Dermatol Venereol |volume=27 Suppl 3 |issue= |pages=36–46 |year=2013 |pmid=23845151 |doi=10.1111/jdv.12165 |url=}}</ref>  
**Plaque-type psoriasis
**Plaque-type psoriasis
**Guttate psoriasis
**Guttate psoriasis
Line 16: Line 16:


{| class="wikitable" font-size: 90%
{| class="wikitable" font-size: 90%
!Type of Psoriasis
! align="center" style="background: #4479BA; color: #FFFFFF; " |Type of Psoriasis
!Typical lesion
! align="center" style="background: #4479BA; color: #FFFFFF; " |Typical Lesion
!Body Distribution
! align="center" style="background: #4479BA; color: #FFFFFF; " |Body Distribution
!Associated conditions<ref name="pmid23845151">{{cite journal |vauthors=Pouplard C, Brenaut E, Horreau C, Barnetche T, Misery L, Richard MA, Aractingi S, Aubin F, Cribier B, Joly P, Jullien D, Le Maître M, Ortonne JP, Paul C |title=Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies |journal=J Eur Acad Dermatol Venereol |volume=27 Suppl 3 |issue= |pages=36–46 |year=2013 |pmid=23845151 |doi=10.1111/jdv.12165 |url=}}</ref><ref name="pmid22751586">{{cite journal |vauthors=Gelfand JM, Yeung H |title=Metabolic syndrome in patients with psoriatic disease |journal=J Rheumatol Suppl |volume=89 |issue= |pages=24–8 |year=2012 |pmid=22751586 |pmc=3670770 |doi=10.3899/jrheum.120237 |url=}}</ref><ref name="pmid23971052">{{cite journal |vauthors=Skroza N, Proietti I, Pampena R, La Viola G, Bernardini N, Nicolucci F, Tolino E, Zuber S, Soccodato V, Potenza C |title=Correlations between psoriasis and inflammatory bowel diseases |journal=Biomed Res Int |volume=2013 |issue= |pages=983902 |year=2013 |pmid=23971052 |pmc=3736484 |doi=10.1155/2013/983902 |url=}}</ref><ref name="pmid2878015">{{cite journal |vauthors=Abel EA, DiCicco LM, Orenberg EK, Fraki JE, Farber EM |title=Drugs in exacerbation of psoriasis |journal=J. Am. Acad. Dermatol. |volume=15 |issue=5 Pt 1 |pages=1007–22 |year=1986 |pmid=2878015 |doi= |url=}}</ref><ref name="pmid12362257">{{cite journal |vauthors=Tauscher AE, Fleischer AB, Phelps KC, Feldman SR |title=Psoriasis and pregnancy |journal=J Cutan Med Surg |volume=6 |issue=6 |pages=561–70 |year=2002 |pmid=12362257 |doi=10.1177/120347540200600608 |url=}}</ref><ref name="pmid2530253">{{cite journal |vauthors=Boyd AS, Menter A |title=Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients |journal=J. Am. Acad. Dermatol. |volume=21 |issue=5 Pt 1 |pages=985–91 |year=1989 |pmid=2530253 |doi= |url=}}</ref>
! align="center" style="background: #4479BA; color: #FFFFFF; " |Associated Conditions
|-
|-
|Plaque-type psoriasis
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Plaque-type psoriasis'''
|
|
* Oval or irregularly shaped
* Oval or irregularly shaped
Line 54: Line 54:
** [[Imiquimod]]
** [[Imiquimod]]
|-
|-
|Guttate psoriasis
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Guttate psoriasis'''
|
|
* Multiple  
* Multiple  
Line 67: Line 67:
* 2–4 weeks after a [[Bacterial|bacterial infection]] of the upper ways, notably [[streptococcal pharyngitis]] in children and adolescents
* 2–4 weeks after a [[Bacterial|bacterial infection]] of the upper ways, notably [[streptococcal pharyngitis]] in children and adolescents
|-
|-
|Generalized pustular psoriasis<ref name="pmid4236712">{{cite journal |vauthors=Baker H, Ryan TJ |title=Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases |journal=Br. J. Dermatol. |volume=80 |issue=12 |pages=771–93 |year=1968 |pmid=4236712 |doi= |url= |issn=}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Generalized pustular psoriasis'''<ref name="pmid4236712">{{cite journal |vauthors=Baker H, Ryan TJ |title=Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases |journal=Br. J. Dermatol. |volume=80 |issue=12 |pages=771–93 |year=1968 |pmid=4236712 |doi= |url= |issn=}}</ref>
|
|
* Four sub-[[types]]:
* Four sub-[[types]]:
Line 93: Line 93:
**Exposure to or withdrawal from drugs
**Exposure to or withdrawal from drugs
|-
|-
|Erythrodermic psoriasis (most severe)
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Erythrodermic psoriasis (most severe)'''
|
|
* Diffuse [[erythema]]
* Diffuse [[erythema]]
Line 106: Line 106:
|}
|}


=== Subphenotypes ===
=== Classification based on sub-phenotypes ===
Several further subphenotypes have been named according to:
Several further sub-phenotypes have been named according to:
* Distribution (localized vs. widespread)
* Distribution (localized vs. widespread)
* Anatomical localization (flexural- also called inverse, scalp, palms/soles/nail)
* Anatomical localization (flexural or inverse, scalp, palms/soles/nail)
* Size (large vs. small)
* Size (large vs. small)
* Thickness (thick vs. thin) of [[Plaque|plaques]]
* Thickness (thick vs. thin) of [[Plaque|plaques]]
* Onset (early vs. late)
* Onset (early vs. late)
* Disease activity (active vs. stable)
* Disease activity (active vs. stable)
===Classification based on severity===
===Classification based on disease severity===
[[Image:Psoriasis severity.jpg|150px|Pie chart showing the distribution of severity among people with psoriasis.]]
<figure-inline><figure-inline>[[Image:Psoriasis severity.jpg|500x500px]]</figure-inline></figure-inline>


Psoriasis is usually graded as:  
Psoriasis is usually graded as:  
* Mild (affecting less than 3% of the body)  
* Mild (affecting less than 3% of the body)  
* Moderate (affecting 3-10% of the body)   
* Moderate (affecting 3-10% of the body)   
* Severe
* Severe (affecting >10% of the body)


=== Degree of severity ===
==== Degree of severity ====
The degree of severity is generally based on the following factors:  
The degree of severity is generally judged based on the following factors:  
*The proportion of body surface area affected
*The proportion of body surface area affected
*Disease activity (degree of plaque redness, thickness and scaling)  
*Disease activity (degree of plaque redness, thickness, and scaling)  
*Response to previous therapies
*Response to previous therapies
*The impact of the disease on the person
*The impact of the disease on the patient's quality of life
===Psoriasis Area Severity Index (PASI)===
====Psoriasis Area Severity Index (PASI)====
The Psoriasis Area Severity Index (PASI) is the most widely used measurement tool for psoriasis. PASI combines the assessment of the severity of [[lesions]] and the area affected into a single score ranging between 0 (no disease) to 72 (maximal disease).<ref>{{cite web |url=http://www.skinandaging.com/article/5394 |title=Psoriasis Update -Skin & Aging |accessdate=2007-07-28 |format= |work=}}</ref> The PASI can be very difficult to use outside of trials, which has led to attempts to simplify the index for clinical use.<ref name="pmid15530297">{{cite journal |author=Louden BA, Pearce DJ, Lang W, Feldman SR |title=A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients |journal=Dermatol. Online J. |volume=10 |issue=2 |pages=7 |year=2004 |pmid=15530297 |doi=}}</ref>
The Psoriasis Area Severity Index (PASI) is the most widely used measurement tool for psoriasis. PASI combines the assessment of the severity of [[lesions]] and the area affected into a single score ranging between 0 (no disease) to 72 (maximal disease).<ref>{{cite web |url=http://www.skinandaging.com/article/5394 |title=Psoriasis Update -Skin & Aging |accessdate=2007-07-28 |format= |work=}}</ref> The PASI can be very difficult to use outside of trials, which has led to attempts to simplify the index for clinical use.<ref name="pmid15530297">{{cite journal |author=Louden BA, Pearce DJ, Lang W, Feldman SR |title=A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients |journal=Dermatol. Online J. |volume=10 |issue=2 |pages=7 |year=2004 |pmid=15530297 |doi=}}</ref>
=== Other types of psoriasis ===
=== Other types of psoriasis ===
*[[Ventral|Flexural]] psoriasis (inverse psoriasis) appears as smooth, [[inflamed]] patches of [[skin]]. It occurs in [[skin fold]]s, particularly around the [[genitals]] (between the [[thigh]] and [[groin]]), [[axillae]], under an overweight [[stomach]] ([[pannus]]), and under the [[breasts]] ([[inframammary fold]]). It is aggravated by [[friction]] and [[sweat]] and is vulnerable to [[fungal]] [[infections]].
*'''[[Ventral|Flexural]] psoriasis:'''
*Nail psoriasis produces a variety of changes in the appearance of [[finger]] and [[toe]] nails. These changes include discoloring under the nail plate, pitting of the nails, lines going across the nails, thickening of the [[skin]] under the nail, and the loosening ([[onycholysis]]) or crumbling of the nail.
**Smooth, [[inflamed]] patches of [[skin]]
*Drug-induced psoriasis
**Occurs in [[skin fold]]s, particularly around the [[genitals]] (between the [[thigh]] and [[groin]]), [[axillae]], under an overweight [[stomach]] ([[pannus]]), and under the [[breasts]] ([[inframammary fold]])
*Napkin psoriasis
**Aggravated by [[friction]] and [[sweat]] and is vulnerable to [[fungal]] [[infections]]
*Seborrheic-like psoriasis
*'''Nail psoriasis:'''
*Pustular psoriasis
**Changes in the appearance of [[finger]] and [[toe]] nails:
<div align="left">
**Discoloration under the nail plate, pitting of the nails, lines going across the nails, thickening of the [[skin]] under the nail, and the loosening ([[onycholysis]]) or crumbling of the nail
<gallery heights="175" widths="175">
*'''Drug-induced psoriasis'''
Image:Psoriasis.jpg|Photograph of an arm covered with plaque psoriasis.
 
Image:Psoriasis nail pitting.jpg|Psoriasis nail pitting
*'''Napkin psoriasis'''
</gallery>
*'''Seborrheic-like psoriasis'''
</div>
*'''Pustular psoriasis'''
 
=== Classification of psoriatic arthritis ===
Psoriatic arthritis may be classified based on severity into the following types:<ref name="urlPsoriasis: Recommendations for broadband and narrowband UVB therapy | American Academy of Dermatology">{{cite web |url=https://www.aad.org/practicecenter/quality/clinical-guidelines/psoriasis/phototherapy-and-photochemotherapy/uvb-therapy |title=Psoriasis: Recommendations for broadband and narrowband UVB therapy &#124; American Academy of Dermatology |format= |work= |accessdate=}}</ref>
* Mild psoriatic arthritis
* Moderate psoriatic arthritis
* Severe psoriatic arthritis
{| class="wikitable" font-size: 90%
! align="center" style="background: #4479BA; color: #FFFFFF; " |Type of psoriatic arthritis
! align="center" style="background: #4479BA; color: #FFFFFF; " |Response to therapy
! align="center" style="background: #4479BA; color: #FFFFFF; " |Quality of life
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Mild psoriatic arthritis'''
|[[Non-steroidal anti-inflammatory drug|NSAIDs]]
|Minimal
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Moderate psoriatic arthritis'''
|Requires [[DMARDs|disease modifying anti-rheumatic drugs]] ([[Disease-modifying antirheumatic drug|DMARD]]) '''or''' [[Tumour necrosis factor|tumor necrosis factor]] blockers  ([[Tumor necrosis factors|TNF-blockers]])
|Daily life tasks affected including mental and physical tasks/ No response to [[Non-steroidal anti-inflammatory drug|NSAIDs]]
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Severe psoriatic arthritis'''
|Requires [[DMARDs|disease modifying anti-rheumatic drugs]] ([[DMARDs|DMARD]]) '''plus''' [[Tumour necrosis factor|tumor necrosis factor]] blockers ([[TNF inhibitor|TNF-blockers]]) '''or''' biologic agents
|Unable to perform major daily tasks of living without pain or dysfunction; large impact on physical and mental functions
|}
 
Psoriatic arthritis also, may be classified into different subtypes as below table:
 
{| class="wikitable"
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Subtype
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease pattern<ref name="pmid158990443">{{cite journal |vauthors=Kruithof E, Baeten D, De Rycke L, Vandooren B, Foell D, Roth J, Cañete JD, Boots AM, Veys EM, De Keyser F |title=Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis |journal=Arthritis Res. Ther. |volume=7 |issue=3 |pages=R569–80 |year=2005 |pmid=15899044 |pmc=1174942 |doi=10.1186/ar1698 |url=}}</ref>
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Percentage of patients affected
! colspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Radiological features<ref name="urlPsoriatic Arthritis Mutilans: Clinical and Radiographic Criteria. A Systematic Review | The Journal of Rheumatology">{{cite web |url=http://www.jrheum.org/content/42/8/1432.long |title=Psoriatic Arthritis Mutilans: Clinical and Radiographic Criteria. A Systematic Review &#124; The Journal of Rheumatology |format= |work= |accessdate=}}</ref>
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Histopathological features<ref name="pmid15899044">{{cite journal |vauthors=Kruithof E, Baeten D, De Rycke L, Vandooren B, Foell D, Roth J, Cañete JD, Boots AM, Veys EM, De Keyser F |title=Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis |journal=Arthritis Res. Ther. |volume=7 |issue=3 |pages=R569–80 |year=2005 |pmid=15899044 |pmc=1174942 |doi=10.1186/ar1698 |url=}}</ref><ref name="pmid11592363">{{cite journal |vauthors=Fraser A, Fearon U, Reece R, Emery P, Veale DJ |title=Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis |journal=Arthritis Rheum. |volume=44 |issue=9 |pages=2024–8 |year=2001 |pmid=11592363 |doi=10.1002/1529-0131(200109)44:9<2024::AID-ART351>3.0.CO;2-K |url=}}</ref><ref name="pmid12563678">{{cite journal |vauthors=Fearon U, Griosios K, Fraser A, Reece R, Emery P, Jones PF, Veale DJ |title=Angiopoietins, growth factors, and vascular morphology in early arthritis |journal=J. Rheumatol. |volume=30 |issue=2 |pages=260–8 |year=2003 |pmid=12563678 |doi= |url=}}</ref>
|-
! style="background:#4479BA; color: #FFFFFF;" + |X-ray
! style="background:#4479BA; color: #FFFFFF;" + |Ultrasonography
! style="background:#4479BA; color: #FFFFFF;" + |<nowiki>Computed tomography|CT scan</nowiki>
! style="background:#4479BA; color: #FFFFFF;" + |MRI
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Classical psoriatic arthritis'''
|
* Involvement of the [[distal interphalangeal joints]]
* Involvement of [[Nail (anatomy)|nails]]
|~5 %
| rowspan="5" |
* Bony [[proliferation]]
* Bone erosion
* "Pencil-in-cup" [[deformity]] (distal head of a bone becomes pointed-like a sharpened pencil, and the neighboring surface becomes rounded due to erosion)
| rowspan="5" |
* [[Synovitis]]
* [[Tenosynovitis]]
* Peritendinitis
* [[Retrocalcaneal bursitis|Retrocalcaneal]] or pre-Achilles bursitis
| rowspan="5" |
* Useful in assessing [[spine]] disease
* [[Joint (anatomy)|Joint]] erosions
* [[Synovitis]]
| rowspan="5" |
* [[Synovitis]] (usually secondary to extrasynovial involvement - helps to differentiate PsA from [[rheumatoid arthritis]])
* [[Gadolinium|Gadolinium contrast]] use can more reliably differentiate PsA from [[rheumatoid arthritis]] by relative enhancement and rate of enhancement on [[MRI]]
* [[Enthesitis]]
* [[Osteitis]]
| rowspan="5" |
* [[Neovascularization]]
* [[Inflammatory cells|Inflammatory]] infiltration with predominantly [[mononuclear cells]] ([[T lymphocytes]], [[B lymphocytes]] and [[Plasma cell|plasma cells]], and [[macrophages]])
* [[Synovial]] lining [[hyperplasia]] 
* High expression of [[E-selectin]]
* [[Synovial]] expression of [[S100A12]]
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" | '''Destructive psoriatic arthritis (arthritis mutilans)'''
|
* Severe [[joint]] destruction


* Involvement of any of the [[Interphalangeal joints|interphalangeal]], [[Metacarpophalangeal joint|metacarpophalangeal]], or [[Metatarsophalangeal joint|metatarsophalangeal]] [[joints]]
* [[Dactylitis]]
* [[Enthesitis]]
* Involvement of [[axial skeleton]]
* Involvement of [[Nail (anatomy)|nails]]
* Digital tapering (opera glass hands)
* [[Joint]] [[ankylosis]]
|< 5 %
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" | '''Symmetric polyarthritis'''
|
* Involvement of [[joints]] on both sides of the body simultaneously
* Most similar to [[rheumatoid arthritis]] 
|~15 %
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" | '''Asymmetric psoriatic arthritis'''
|
* Involvement of < 3 [[joints]]
* Does not occur in the same [[joints]] on both sides of the body
|~70 %
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" | '''Ankylosing spondylitis-like psoriatic arthritis'''
|
* Stiffness of the [[spine]] or neck, but can also affect the hands and feet, in a similar fashion to symmetric arthritis
|~ 5 %
|}


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
{{WH}}
{{WS}}


[[Category:Primary care]]
[[Category:Dermatology]]
[[Category:Dermatology]]
[[Category:Needs overview]]
[[Category:Disease]]
{{WH}}
{{WS}}

Latest revision as of 23:52, 29 July 2020

Psoriasis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Psoriasis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X-ray

Ultrasound

CT scan

MRI

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Psoriasis classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Psoriasis classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Psoriasis classification

CDC on Psoriasis classification

Psoriasis classification in the news

Blogs on Psoriasis classification

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Psoriasis classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2]

Overview

Psoriasis can be classified according to clinical appearance, morphology, and localization. According to the International Psoriasis Council, psoriasis may be classified into four subtypes: plaque-type psoriasis, guttate psoriasis, generalized pustular psoriasis (GPP), and erythroderma. Several further subphenotypes have been named according to distribution (localized vs. widespread), anatomical localization (flexural or inverse, scalp, palms/soles/nail), size (large vs. small) and thickness (thick vs. thin) of plaques, onset (early vs. late), and disease activity (active vs. stable).

Classification

Classification based on clinical appearance, morphology, and localization

  • The International Psoriasis Council classifies psoriasis into four main forms, according to clinical appearance, morphology and localization:[1][2][3][4][5][6]
    • Plaque-type psoriasis
    • Guttate psoriasis
    • Generalized Pustular Psoriasis (GPP)
    • Erythroderma
Type of Psoriasis Typical Lesion Body Distribution Associated Conditions
Plaque-type psoriasis
  • Oval or irregularly shaped
  • Erythematous
  • Sharply demarcated
  • Raised plaques covered by silvery scales
  • Large plaques >3cm
  • Small plaques <3cm

Triggers include:

Guttate psoriasis
  • Multiple
  • Small
  • Drop-shaped
  • Scaly plaques
Generalized pustular psoriasis[7]
  • Generalized
Erythrodermic psoriasis (most severe)
  • >70 % of the body surface area

Classification based on sub-phenotypes

Several further sub-phenotypes have been named according to:

  • Distribution (localized vs. widespread)
  • Anatomical localization (flexural or inverse, scalp, palms/soles/nail)
  • Size (large vs. small)
  • Thickness (thick vs. thin) of plaques
  • Onset (early vs. late)
  • Disease activity (active vs. stable)

Classification based on disease severity

<figure-inline><figure-inline></figure-inline></figure-inline>

Psoriasis is usually graded as:

  • Mild (affecting less than 3% of the body)
  • Moderate (affecting 3-10% of the body)
  • Severe (affecting >10% of the body)

Degree of severity

The degree of severity is generally judged based on the following factors:

  • The proportion of body surface area affected
  • Disease activity (degree of plaque redness, thickness, and scaling)
  • Response to previous therapies
  • The impact of the disease on the patient's quality of life

Psoriasis Area Severity Index (PASI)

The Psoriasis Area Severity Index (PASI) is the most widely used measurement tool for psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score ranging between 0 (no disease) to 72 (maximal disease).[8] The PASI can be very difficult to use outside of trials, which has led to attempts to simplify the index for clinical use.[9]

Other types of psoriasis

  • Napkin psoriasis
  • Seborrheic-like psoriasis
  • Pustular psoriasis

Classification of psoriatic arthritis

Psoriatic arthritis may be classified based on severity into the following types:[10]

  • Mild psoriatic arthritis
  • Moderate psoriatic arthritis
  • Severe psoriatic arthritis
Type of psoriatic arthritis Response to therapy Quality of life
Mild psoriatic arthritis NSAIDs Minimal
Moderate psoriatic arthritis Requires disease modifying anti-rheumatic drugs (DMARD) or tumor necrosis factor blockers (TNF-blockers) Daily life tasks affected including mental and physical tasks/ No response to NSAIDs
Severe psoriatic arthritis Requires disease modifying anti-rheumatic drugs (DMARD) plus tumor necrosis factor blockers (TNF-blockers) or biologic agents Unable to perform major daily tasks of living without pain or dysfunction; large impact on physical and mental functions

Psoriatic arthritis also, may be classified into different subtypes as below table:

Subtype Disease pattern[11] Percentage of patients affected Radiological features[12] Histopathological features[13][14][15]
X-ray Ultrasonography Computed tomography|CT scan MRI
Classical psoriatic arthritis ~5 %
  • Bony proliferation
  • Bone erosion
  • "Pencil-in-cup" deformity (distal head of a bone becomes pointed-like a sharpened pencil, and the neighboring surface becomes rounded due to erosion)
Destructive psoriatic arthritis (arthritis mutilans) < 5 %
Symmetric polyarthritis ~15 %
Asymmetric psoriatic arthritis
  • Does not occur in the same joints on both sides of the body
 ~70 %
Ankylosing spondylitis-like psoriatic arthritis
  • Stiffness of the spine or neck, but can also affect the hands and feet, in a similar fashion to symmetric arthritis
 ~ 5 %

References

  1. ↑ Boyd AS, Menter A (1989). "Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients". J. Am. Acad. Dermatol. 21 (5 Pt 1): 985–91. PMID 2530253.
  2. ↑ Tauscher AE, Fleischer AB, Phelps KC, Feldman SR (2002). "Psoriasis and pregnancy". J Cutan Med Surg. 6 (6): 561–70. doi:10.1177/120347540200600608. PMID 12362257.
  3. ↑ Abel EA, DiCicco LM, Orenberg EK, Fraki JE, Farber EM (1986). "Drugs in exacerbation of psoriasis". J. Am. Acad. Dermatol. 15 (5 Pt 1): 1007–22. PMID 2878015.
  4. ↑ Skroza N, Proietti I, Pampena R, La Viola G, Bernardini N, Nicolucci F, Tolino E, Zuber S, Soccodato V, Potenza C (2013). "Correlations between psoriasis and inflammatory bowel diseases". Biomed Res Int. 2013: 983902. doi:10.1155/2013/983902. PMC 3736484. PMID 23971052.
  5. ↑ Gelfand JM, Yeung H (2012). "Metabolic syndrome in patients with psoriatic disease". J Rheumatol Suppl. 89: 24–8. doi:10.3899/jrheum.120237. PMC 3670770. PMID 22751586.
  6. ↑ Pouplard C, Brenaut E, Horreau C, Barnetche T, Misery L, Richard MA, Aractingi S, Aubin F, Cribier B, Joly P, Jullien D, Le Maître M, Ortonne JP, Paul C (2013). "Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies". J Eur Acad Dermatol Venereol. 27 Suppl 3: 36–46. doi:10.1111/jdv.12165. PMID 23845151.
  7. ↑ Baker H, Ryan TJ (1968). "Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases". Br. J. Dermatol. 80 (12): 771–93. PMID 4236712.
  8. ↑ "Psoriasis Update -Skin & Aging". Retrieved 2007-07-28.
  9. ↑ Louden BA, Pearce DJ, Lang W, Feldman SR (2004). "A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients". Dermatol. Online J. 10 (2): 7. PMID 15530297.
  10. ↑ "Psoriasis: Recommendations for broadband and narrowband UVB therapy | American Academy of Dermatology".
  11. ↑ Kruithof E, Baeten D, De Rycke L, Vandooren B, Foell D, Roth J, Cañete JD, Boots AM, Veys EM, De Keyser F (2005). "Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis". Arthritis Res. Ther. 7 (3): R569–80. doi:10.1186/ar1698. PMC 1174942. PMID 15899044.
  12. ↑ "Psoriatic Arthritis Mutilans: Clinical and Radiographic Criteria. A Systematic Review | The Journal of Rheumatology".
  13. ↑ Kruithof E, Baeten D, De Rycke L, Vandooren B, Foell D, Roth J, Cañete JD, Boots AM, Veys EM, De Keyser F (2005). "Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis". Arthritis Res. Ther. 7 (3): R569–80. doi:10.1186/ar1698. PMC 1174942. PMID 15899044.
  14. ↑ Fraser A, Fearon U, Reece R, Emery P, Veale DJ (2001). "Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis". Arthritis Rheum. 44 (9): 2024–8. doi:10.1002/1529-0131(200109)44:9<2024::AID-ART351>3.0.CO;2-K. PMID 11592363.
  15. ↑ Fearon U, Griosios K, Fraser A, Reece R, Emery P, Jones PF, Veale DJ (2003). "Angiopoietins, growth factors, and vascular morphology in early arthritis". J. Rheumatol. 30 (2): 260–8. PMID 12563678.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Psoriasis_classification&oldid=1642559"